Two potential treatments for cystic fibrosis have been recommended for designation as orphan medicinal products in Europe, the European Medicines Agency said on 10 July 2008. The two treatments bring to 27 the number of drugs either designated as orphans or recommended for designation for this indication. Despite this high number none of the cystic fibrosis treatments has received a marketing authorisation. This has prompted the EMEA to issue a new guidance document for developers of cystic fibrosis products.
